The Prognostic Values of a Novel Preoperative Inflammation-Based Score in Japanese Patients With Non-Small Cell Lung Cancer

被引:4
|
作者
Tomita, Masaki [1 ]
Ayabe, Takanori [1 ]
Maeda, Ryo [1 ]
Nakamura, Kunihide [1 ,2 ]
机构
[1] Univ Miyazaki, Fac Med, Dept Thorac & Breast Surg, Kihara 5200, Miyazaki, Miyazaki 8891692, Japan
[2] Univ Miyazaki, Fac Med, Dept Cardiovasc Surg, Kihara 5200, Miyazaki, Miyazaki 8891692, Japan
关键词
Novel inflammation-based core; Non-small cell lung cancer; Surgery; Cancer-specific survival; C-REACTIVE PROTEIN; BODY-MASS INDEX; LYMPHOCYTE RATIO; SURVIVAL; NEUTROPHIL;
D O I
10.14740/wjon1222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Several previous researchers have investigated the prognostic value of the combinations of systemic inflammatory markers. However, the prognostic power of these systemic inflammatory markers is not identical. We aimed to establish a novel prognostic score based on systemic inflammatory markers. Methods: Four hundred non-small cell lung cancer (NSCLC) patients who underwent surgery and were followed more than 5 years were included. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. Results: Among systemic inflammatory markers which were used for the previously reported indexes, preoperative serum C-reactive protein (CRP) and body mass index (BMI) were independent prognostic markers in multivariate analysis, while serum albumin level, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio were not. Based on this result, a novel score was established. Patients with both normal CRP (< 0.13 ng/dL) and high BMI (> 20.6 kg/m(2)) were allocated a score of 0. Patients in whom only one of these abnormalities was present were allocated a score of 1, whilst those with both high CRP and low BMI were given a score of 2. Patients with score 0 had 84.44% of 5-year cancer-specific survival, while patients with score 1 - 2 had a 61.88%. On multivariate analysis, this novel score was an independent prognostic factor. Conclusion: This novel score based on CRP and BMI might serve as an efficient prognostic indicator in resected NSCLC.
引用
收藏
页码:176 / 180
页数:5
相关论文
共 50 条
  • [31] A systemic inflammation-based prognostic scores (mGPS) to predict overall survival of patients with small cell lung cancer
    Zhang, Li
    Zhou, Ting
    Hu, Zhihuang
    Hou, Xue
    Huang, Yan
    Zhao, Hongyun
    Zhao, YuanYuan
    Liang, Wenhua
    Fang, Wenfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer
    Trape, Jaume
    Montesinos, Jesus
    Catot, Silvia
    Buxo, Josep
    Franquesa, Josefina
    Sala, Maria
    Domenech, Montserrat
    Sant, Francesc
    Badal, Josep M.
    Arnau, Anna
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2012, 27 (03): : 257 - 262
  • [33] Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer
    Forrest, LM
    McMillan, DC
    McArdle, CS
    Angerson, WJ
    Dunlop, DJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (09) : 1704 - 1706
  • [34] Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis
    Yang, Chenli
    Ren, Guangshu
    Yang, Qingqing
    FRONTIERS IN SURGERY, 2023, 9
  • [35] Prognostic factors for patients with non-small cell lung cancer
    Rosvold, E
    CURRENT PROBLEMS IN CANCER, 1996, 20 (04) : 272 - 278
  • [36] A PROGNOSTIC SCORE BASED ON CLINICAL FACTORS AND BIOMARKERS FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Trape, J.
    Montesinos, J.
    Catot, S.
    Buxo, J.
    Franquesa, J.
    Sala, M.
    Domenech, M.
    Sant, F.
    Badal, J. M.
    TUMOR BIOLOGY, 2010, 31 : S49 - S49
  • [37] Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer
    L M Forrest
    D C McMillan
    C S McArdle
    W J Angerson
    D J Dunlop
    British Journal of Cancer, 2004, 90 : 1704 - 1706
  • [38] Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
    Valente, M. C. Alves
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Sousa, C.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [39] Prognostic Significance of Pre- and Postoperative Glasgow Prognostic Score for Patients with Non-small Cell Lung Cancer
    Tomita, Masaki
    Ayabe, Takanori
    Chosa, Eiichi
    Nakamura, Kunihide
    ANTICANCER RESEARCH, 2014, 34 (06) : 3137 - 3140
  • [40] Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
    Pan, Mingmei
    Zhao, Yun
    He, Jianbo
    Wu, Huanqiong
    Pan, Yujia
    Yu, Qitao
    Zhou, Shaozhang
    JOURNAL OF CANCER, 2021, 12 (08): : 2395 - 2402